Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation

Christopher S. Smillie, Jenny Sauk, Dirk Gevers, Jonathan Friedman, Jaeyun Sung, Ilan Youngster, Elizabeth L. Hohmann, Christopher Staley, Alexander Khoruts, Michael J. Sadowsky, Jessica R. Allegretti, Mark B. Smith, Ramnik J. Xavier, Eric J. Alm

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient's gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time. We find that engraftment can be predicted largely from the abundance and phylogeny of bacteria in the donor and the pre-FMT patient. Furthermore, donor strains within a species engraft in an all-or-nothing manner and previously undetected strains frequently colonize patients receiving FMT. We validated these findings for metabolic syndrome, suggesting that the same principles of engraftment extend to other indications. Smillie et al. profile the gut microbiota of recurrent Clostridium difficile patients during fecal microbiota transplantation (FMT) and uncover the principles of microbiota engraftment in humans. They validate their findings across several FMT datasets and in another disease context, metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)229-240.e5
JournalCell Host and Microbe
Volume23
Issue number2
DOIs
StatePublished - Feb 14 2018
Externally publishedYes

Fingerprint

Clostridium difficile
Microbiota
Tissue Donors
Bacteria
Clostridium Infections
Metabolic Diseases
Statistical Models
Phylogeny
Fecal Microbiota Transplantation
Genotype
Therapeutics
Datasets
Gastrointestinal Microbiome

Keywords

  • bacterial engraftment
  • C. difficile
  • Clostridium difficile
  • fecal microbiota transplant
  • fecal transplant
  • FMT
  • human microbiome
  • human microbiota
  • strain inference
  • strain tracking

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Cite this

Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. / Smillie, Christopher S.; Sauk, Jenny; Gevers, Dirk; Friedman, Jonathan; Sung, Jaeyun; Youngster, Ilan; Hohmann, Elizabeth L.; Staley, Christopher; Khoruts, Alexander; Sadowsky, Michael J.; Allegretti, Jessica R.; Smith, Mark B.; Xavier, Ramnik J.; Alm, Eric J.

In: Cell Host and Microbe, Vol. 23, No. 2, 14.02.2018, p. 229-240.e5.

Research output: Contribution to journalArticle

Smillie, CS, Sauk, J, Gevers, D, Friedman, J, Sung, J, Youngster, I, Hohmann, EL, Staley, C, Khoruts, A, Sadowsky, MJ, Allegretti, JR, Smith, MB, Xavier, RJ & Alm, EJ 2018, 'Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation', Cell Host and Microbe, vol. 23, no. 2, pp. 229-240.e5. https://doi.org/10.1016/j.chom.2018.01.003
Smillie, Christopher S. ; Sauk, Jenny ; Gevers, Dirk ; Friedman, Jonathan ; Sung, Jaeyun ; Youngster, Ilan ; Hohmann, Elizabeth L. ; Staley, Christopher ; Khoruts, Alexander ; Sadowsky, Michael J. ; Allegretti, Jessica R. ; Smith, Mark B. ; Xavier, Ramnik J. ; Alm, Eric J. / Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. In: Cell Host and Microbe. 2018 ; Vol. 23, No. 2. pp. 229-240.e5.
@article{c0adf179960347949869480581fe1038,
title = "Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation",
abstract = "Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient's gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time. We find that engraftment can be predicted largely from the abundance and phylogeny of bacteria in the donor and the pre-FMT patient. Furthermore, donor strains within a species engraft in an all-or-nothing manner and previously undetected strains frequently colonize patients receiving FMT. We validated these findings for metabolic syndrome, suggesting that the same principles of engraftment extend to other indications. Smillie et al. profile the gut microbiota of recurrent Clostridium difficile patients during fecal microbiota transplantation (FMT) and uncover the principles of microbiota engraftment in humans. They validate their findings across several FMT datasets and in another disease context, metabolic syndrome.",
keywords = "bacterial engraftment, C. difficile, Clostridium difficile, fecal microbiota transplant, fecal transplant, FMT, human microbiome, human microbiota, strain inference, strain tracking",
author = "Smillie, {Christopher S.} and Jenny Sauk and Dirk Gevers and Jonathan Friedman and Jaeyun Sung and Ilan Youngster and Hohmann, {Elizabeth L.} and Christopher Staley and Alexander Khoruts and Sadowsky, {Michael J.} and Allegretti, {Jessica R.} and Smith, {Mark B.} and Xavier, {Ramnik J.} and Alm, {Eric J.}",
year = "2018",
month = "2",
day = "14",
doi = "10.1016/j.chom.2018.01.003",
language = "English (US)",
volume = "23",
pages = "229--240.e5",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation

AU - Smillie, Christopher S.

AU - Sauk, Jenny

AU - Gevers, Dirk

AU - Friedman, Jonathan

AU - Sung, Jaeyun

AU - Youngster, Ilan

AU - Hohmann, Elizabeth L.

AU - Staley, Christopher

AU - Khoruts, Alexander

AU - Sadowsky, Michael J.

AU - Allegretti, Jessica R.

AU - Smith, Mark B.

AU - Xavier, Ramnik J.

AU - Alm, Eric J.

PY - 2018/2/14

Y1 - 2018/2/14

N2 - Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient's gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time. We find that engraftment can be predicted largely from the abundance and phylogeny of bacteria in the donor and the pre-FMT patient. Furthermore, donor strains within a species engraft in an all-or-nothing manner and previously undetected strains frequently colonize patients receiving FMT. We validated these findings for metabolic syndrome, suggesting that the same principles of engraftment extend to other indications. Smillie et al. profile the gut microbiota of recurrent Clostridium difficile patients during fecal microbiota transplantation (FMT) and uncover the principles of microbiota engraftment in humans. They validate their findings across several FMT datasets and in another disease context, metabolic syndrome.

AB - Fecal microbiota transplantation (FMT) from healthy donor to patient is a treatment for microbiome-associated diseases. Although the success of FMT requires donor bacteria to engraft in the patient's gut, the forces governing engraftment in humans are unknown. Here we use an ongoing clinical experiment, the treatment of recurrent Clostridium difficile infection, to uncover the rules of engraftment in humans. We built a statistical model that predicts which bacterial species will engraft in a given host, and developed Strain Finder, a method to infer strain genotypes and track them over time. We find that engraftment can be predicted largely from the abundance and phylogeny of bacteria in the donor and the pre-FMT patient. Furthermore, donor strains within a species engraft in an all-or-nothing manner and previously undetected strains frequently colonize patients receiving FMT. We validated these findings for metabolic syndrome, suggesting that the same principles of engraftment extend to other indications. Smillie et al. profile the gut microbiota of recurrent Clostridium difficile patients during fecal microbiota transplantation (FMT) and uncover the principles of microbiota engraftment in humans. They validate their findings across several FMT datasets and in another disease context, metabolic syndrome.

KW - bacterial engraftment

KW - C. difficile

KW - Clostridium difficile

KW - fecal microbiota transplant

KW - fecal transplant

KW - FMT

KW - human microbiome

KW - human microbiota

KW - strain inference

KW - strain tracking

UR - http://www.scopus.com/inward/record.url?scp=85044337697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044337697&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2018.01.003

DO - 10.1016/j.chom.2018.01.003

M3 - Article

C2 - 29447696

AN - SCOPUS:85044337697

VL - 23

SP - 229-240.e5

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 2

ER -